November #41 : Tomato, Tomahto - by Gabi Horn

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join

Back to home » Archives » POZ Magazine issues

Table of Contents

Organizing Inside

Concealed Weapon

Long Day's Journey

Lethal Lottery

Natural Bootleg


One for the Books

Flying Ace

Tucker: The Man and His Dream

Hatch a Plan

Signs of Life

The Trouble With Norvir

Engine No. 48,000


To the Editor

None the Wiser

Tomato, Tomahto

Enter at Your Own Risk

Say What

Swim Lessons

Stigma Enigma

Daddy’s Helper

Nushawn on the Block

Privacy Parsed

Equal Protection for All

“Just Say No” to Welfare

Ms. Thurman Goes to Washington

POZ Picks

Show and Tell

The Eye in the Storm

Get Our Phil

POZarazzi: AIDS! The Musical

Verse: Amirah


One for the Books

Flying Ace

Tucker: The Man and His Dream

Hatch a Plan

Poetic License

Poetic License

The Vision Thing

Stop the World, I want to Get Off

Surviving Behind the Walls

Prick and Tell

The Bitter End

Draining the Reservoirs

Testosterone Beats Fatigue

Carnitine Boosts CD4s

Multivitamins for Moms

Bleach Works

HIV Med Line

Weight List

Do the Hustle

A Mantra a Day

Attack of the Monster Combo

Helper Cells

He Still Is What He Is

Dark Secrets

Most Popular Lessons

The HIV Life Cycle


Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV

email print

November 1998

Tomato, Tomahto

by Gabi Horn

Brits nix early treatment

In keeping with stereotypes—pushy Americans and reserved Britons—the UK’s updated HIV treatment guidelines, published in July’s Lancet, recommend starting therapy later than the U.S. standard: Brits say begin as CD4 counts fall toward 350; the official Yank yarn is to start at 500.

“The British have always been a bit more conservative about when to start, and for good reason,” said the AIDS Treatment Data Network’s Rich Jefferys, a transplanted Londoner. “Starting treatment is a risk/benefit equation: At what point is someone at enough risk of disease progression that they’ll benefit from it?” With a normal CD4 range  between 400 and 1,200, Jefferys said, an asymptomatic HIVer with 500 CD4s who starts therapy may be overzealous.

The 350 reserved option may be the U.S. import to invest in. After July’s World AIDS Conference, even San Francisco General Hospital’s Dr. Paul Volberding, a leading early-interventionist since AZT, said: “Don’t you suspect we have, if anything, erred on the side of recommending therapy too early? Putting it off is something we need to consider.” Blimey!, Jefferys said. “It’s rather scary that he’s saying that. My hunch is it means he’s seeing some pretty nasty things in his patients.”

[Go to top]

Facebook Twitter Google+ MySpace YouTube Tumblr Flickr Instagram
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar
POZ on Twitter

Ask POZ Pharmacist

Talk to Us
Did you participate in an event for National Black HIV/AIDS Awareness Day 2016?


more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2016 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.